HK Stock Market Move | ZAI LAB (09688) rises more than 4% and reaches a global clinical cooperation with AstraZeneca on the use of Zoci combined with Tarlatuzumab for small cell lung cancer.

09:48 02/04/2026

Zai Ding Pharmaceutical (09688) rose more than 4%, as of the time of publication, up 4.22% to 15.79 Hong Kong dollars, with a turnover of 98.0073 million Hong Kong dollars.

ZAI LAB (09688) rose by over 4%, as of the time of publication, it has increased by 4.22%, reaching 15.79 Hong Kong dollars, with a trading volume of 98.073 million Hong Kong dollars. On the news front, on April 1, ZAI LAB announced a global clinical research collaboration with Amgen to evaluate the antibody-drug conjugate (ADC) zocilurtatug pelitecan (zoci, formerly known as ZL-1310) targeting delta-like ligand 3 (DLL3) in clinical stage, together with Amgen's IMDELLTRA (talatuamab), a BiTE therapy targeting DLL3, for the treatment of extensive-stage small cell lung cancer (ES-SCLC) patients. As part of this collaboration agreement, Amgen will initiate a global Phase 1b study to evaluate the safety and efficacy of zoci in combination with IMDELLTRA in ES-SCLC patients. ZAI LAB will retain full ownership of zoci and will provide Amgen with clinical trial medication.

HK Stock Market Move | Soho Holly Futures (03678) falls more than 3% to hit a new near one-year low, with net profit last year plunging by almost 87% year-on-year.

HK Stock Market Move | GALAXIS TECH (02729) surged nearly 7% against the market trend, focusing on intelligent in-house logistics in the Siasun Robot & Automation sector. Revenue in September increased by over 60% compared to 25 years ago.

HK Stock Market Move | YADEA (01585) rose more than 4%, with strong year-on-year growth in Southeast Asia revenue. Institutions are optimistic about the company's accelerated progress in overseas business.

HK Stock Market Move | Soho Holly Futures (03678) falls more than 3% to hit a new near one-year low, with net profit last year plunging by almost 87% year-on-year.